- Home
- TCBX vs DSGN Comparison
TCBX vs DSGN Comparison
Compare TCBX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBX
- DSGN
- Stock Information
- Founded
- TCBX 2008
- DSGN 2017
- Country
- TCBX United States
- DSGN United States
- Employees
- TCBX N/A
- DSGN N/A
- Industry
- TCBX Banks
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- TCBX Finance
- DSGN Health Care
- Exchange
- TCBX Nasdaq
- DSGN Nasdaq
- Market Cap
- TCBX 481.8M
- DSGN 418.1M
- IPO Year
- TCBX 2021
- DSGN 2021
- Fundamental
- Price
- TCBX $38.35
- DSGN $9.49
- Analyst Decision
- TCBX Hold
- DSGN Buy
- Analyst Count
- TCBX 4
- DSGN 1
- Target Price
- TCBX $41.67
- DSGN $13.00
- AVG Volume (30 Days)
- TCBX 54.4K
- DSGN 455.5K
- Earning Date
- TCBX 10-22-2025
- DSGN 11-05-2025
- Dividend Yield
- TCBX N/A
- DSGN N/A
- EPS Growth
- TCBX 38.90
- DSGN N/A
- EPS
- TCBX 3.56
- DSGN N/A
- Revenue
- TCBX $192,224,000.00
- DSGN N/A
- Revenue This Year
- TCBX $24.66
- DSGN N/A
- Revenue Next Year
- TCBX $17.56
- DSGN N/A
- P/E Ratio
- TCBX $10.77
- DSGN N/A
- Revenue Growth
- TCBX 20.96
- DSGN N/A
- 52 Week Low
- TCBX $25.17
- DSGN $2.60
- 52 Week High
- TCBX $41.25
- DSGN $9.85
- Technical
- Relative Strength Index (RSI)
- TCBX 55.70
- DSGN 72.66
- Support Level
- TCBX $36.00
- DSGN $8.21
- Resistance Level
- TCBX $37.69
- DSGN $8.80
- Average True Range (ATR)
- TCBX 1.06
- DSGN 0.72
- MACD
- TCBX 0.20
- DSGN 0.20
- Stochastic Oscillator
- TCBX 79.33
- DSGN 84.86
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.